MAPK3 and acute myeloid leukemia: Treatment of Thp-1 cells with AML-exos significantly increased phosphorylation of ERK1/2 and Smad2/3 (Figure 6B), effects that were attenuated by the TGF-β receptor inhibitor ITD1.